COVID heralds a faster future for drug development (if stakeholders can collaborate)COVID-19 has been a trial-by-fire showing just how quickly drugs and vaccines can be developed under the right Share XCOVID heralds a faster future for drug development (if stakeholders can collaborate)https://pharmaphorum.com/views-and-analysis/covid-heralds-a-faster-future-for-drug-development-if-stakeholders-can-work-together/
Gilead scores US approval for breast cancer drug that wowed ESMOGilead’s $21 billion purchase of Immunomedics and its potential blockbuster Trodelvy continues to pay off, as the drug Share XGilead scores US approval for breast cancer drug that wowed ESMOhttps://pharmaphorum.com/news/gilead-scores-us-approval-for-breast-cancer-drug-that-wowed-esmo/
Acadia puts blame on FDA as Nuplazid rejected for dementiaAcadia Pharmaceuticals is butting heads with US regulators again, this time over the FDA’s decision to reject its Share XAcadia puts blame on FDA as Nuplazid rejected for dementiahttps://pharmaphorum.com/news/acadia-blame-fda-nuplazid-rejected-dementia/
Country focus: Hungary carves out a niche in digital pharmaAI simulated cell company Turbine is just one of many digital drug discovery firms on the rise in Share XCountry focus: Hungary carves out a niche in digital pharmahttps://pharmaphorum.com/digital/country-focus-hungary-carves-out-a-niche-in-digital-pharma/
Roche expands COVID testing portfolio with $1.8bn GenMark dealRoche has said it will pay $1.8 billion for molecular testing company GenMark, boosting the Swiss company’s diagnostic Share XRoche expands COVID testing portfolio with $1.8bn GenMark dealhttps://pharmaphorum.com/news/roche-expands-covid-testing-portfolio-with-1-8bn-genmark-deal/
Patient involvement in trial design: looking to the futureCOVID-19 has transformed the way we think about patient participation in trial design – but there are still Share XPatient involvement in trial design: looking to the futurehttps://pharmaphorum.com/patients/patient-involvement-in-trial-design-looking-to-the-future/
Ipsen’s John Chaddock on making neurotoxins a priority for healthcare systemsInjected neurotoxins can be incredibly potent in treating spasticity from neurological diseases, but the field doesn’t always get Share XIpsen’s John Chaddock on making neurotoxins a priority for healthcare systemshttps://pharmaphorum.com/r-d/views-analysis-r-d/ipsens-john-chaddock-on-making-neurotoxins-a-priority-for-healthcare-systems/
Novo Nordisk’s semaglutide effective against obesity in new trialNovo Nordisk’s hopes of getting semaglutide approved for obesity management may have received a boost, with a new, Share XNovo Nordisk’s semaglutide effective against obesity in new trialhttps://pharmaphorum.com/news/novo-nordisks-semaglutide-effective-obesity-new-trial/
Gene editing: beyond the hypeGenome editing is an exciting but still nascent field, and companies in the area face as many obstacles Share XGene editing: beyond the hypehttps://pharmaphorum.com/r-d/views-analysis-r-d/genome-editing-sangamo-beyond-the-hype/
